Cresco Labs Inc. (OTCMKTS:CRLBF – Get Rating) – Stock analysts at Pi Financial raised their FY2022 EPS estimates for shares of Cresco Labs in a report released on Wednesday, August 3rd. Pi Financial analyst J. Zandberg now anticipates that the company will earn ($0.12) per share for the year, up from their prior forecast of ($0.13). Pi Financial has a “Buy” rating on the stock. The consensus estimate for Cresco Labs’ current full-year earnings is ($0.03) per share.
Cresco Labs (OTCMKTS:CRLBF – Get Rating) last issued its quarterly earnings results on Wednesday, May 18th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.10). The business had revenue of $214.39 million for the quarter, compared to analyst estimates of $210.71 million. Cresco Labs had a negative return on equity of 1.46% and a negative net margin of 37.03%.
Cresco Labs Stock Performance
Shares of CRLBF stock opened at $3.51 on Friday. The company has a market cap of $948.95 million and a price-to-earnings ratio of -2.95. The stock has a 50 day simple moving average of $3.23 and a 200-day simple moving average of $4.85. Cresco Labs has a 12-month low of $2.42 and a 12-month high of $11.67. The company has a current ratio of 1.21, a quick ratio of 0.73 and a debt-to-equity ratio of 0.77.
Cresco Labs Company Profile
Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand, as well as cannabis products under the Reserve brand.
- Get a free copy of the StockNews.com research report on Cresco Labs (CRLBF)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Cresco Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cresco Labs and related companies with MarketBeat.com's FREE daily email newsletter.